Home Protein Tyrosine Kinase Ephrin receptor

Ephrin receptor

Ephrin receptor Products

  • All (8)
  • Ephrin receptor Inhibitors (5)
  • Ephrin receptor Antibodies (2)
  • New Ephrin receptor Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2202 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Nat Commun, 2024, 15(1):5894
Eur J Pharmacol, 2024, 983:177000
Cell Rep, 2022, 41(11):111827
S8573 Sitravatinib (MGCD516) Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
JCI Insight, 2022, e148717
Cancers (Basel), 2021, 13(21)5474
Cancers (Basel), 2020, 12(1)
S0256 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors.
E2835 NVP-BHG712 isomer NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EphA2 and EphB4.
A2897 Ifabotuzumab (Anti-EphA3) Ifabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD.
E0614 AWL-II-38.3 AWL-II-38.3 is a potent Ephrin type-A receptor 3 (EphA3) kinase inhibitor.
A2511 Anti-EphA2 (MEDI-547) Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD.
S6515 ALW II-41-27 ALW II-41-27 (compound 7) is a potent inhibitor of Eph receptor tyrosine kinase with Kd of 12 nM for EphA2.
S2202 NVP-BHG712 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
Nat Commun, 2024, 15(1):5894
Eur J Pharmacol, 2024, 983:177000
Cell Rep, 2022, 41(11):111827
S8573 Sitravatinib (MGCD516) Sitravatinib (MGCD516, MG-516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.
JCI Insight, 2022, e148717
Cancers (Basel), 2021, 13(21)5474
Cancers (Basel), 2020, 12(1)
S0256 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors.
E0614 AWL-II-38.3 AWL-II-38.3 is a potent Ephrin type-A receptor 3 (EphA3) kinase inhibitor.
S6515 ALW II-41-27 ALW II-41-27 (compound 7) is a potent inhibitor of Eph receptor tyrosine kinase with Kd of 12 nM for EphA2.
A2897 Ifabotuzumab (Anti-EphA3) Ifabotuzumab (Anti-EphA3) is a monoclonal antibody against EphA3. MW: 145.28 KD.
A2511 Anti-EphA2 (MEDI-547) Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD.

Choose Selective Ephrin receptor Inhibitors

Ephrin receptorSignaling Pathway

Ephrin receptor信号通路图
Tags: Ephrin receptor inhibitor|Ephrin receptor agonist|Ephrin receptor activator|Ephrin receptor inducer|Ephrin receptor antagonist|Ephrin receptor signaling pathway|Ephrin receptor assay kit